Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid To Focus On Product Promotion Under Chairman Green

Executive Summary

Rite Aid's turnaround plan includes a revised marketing strategy that will emphasize promotion of products, sales and services, the company said.

You may also be interested in...



Rite Aid Sales Slow With OTC Claritin, HRT Slump; Growing Rx Count Is Focus

Rite Aid is attributing its slower growth in prescription drug sales to reduced hormone therapy demand and the Claritin OTC switch

Rite Aid Sales Slow With OTC Claritin, HRT Slump; Growing Rx Count Is Focus

Rite Aid is attributing its slower growth in prescription drug sales to reduced hormone therapy demand and the Claritin OTC switch

Rite Aid Heads West To Fill Executive Positions, Taps Fred Meyer Execs

Rite Aid's appointment of four former Fred Meyer executives to its top management positions brings a change to the drug store chain's west coast business strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel